Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patients

Netherlands Journal of Medicine

Volumn 74, Issue 5, 2016, Pages 225-227

  Gevers, T J G ^a   Burger, D ^b   Schipper Reintjes, E ^a   Kooistra, M P ^a   Richter, C ^a  

^a RIJNSTATE HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DACLATASVIR; DRUG METABOLITE; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; VIRUS RNA;

ADULT; ANEMIA; CARDIOTOXICITY; CASE REPORT; CHILD PUGH SCORE; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LETTER; LIVER CIRRHOSIS; LIVER TOXICITY; LOADING DRUG DOSE; LOW DRUG DOSE; MALE; MIDDLE AGED; RECOMMENDED DRUG DOSE; REFLUX NEPHROPATHY; VIRAL CLEARANCE; BLOOD; COMPLICATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; KIDNEY FAILURE, CHRONIC; SUSTAINED VIROLOGIC RESPONSE; VIRUS LOAD;

ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; KIDNEY FAILURE, CHRONIC; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RENAL DIALYSIS; RIBAVIRIN; RNA, VIRAL; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; VIRAL LOAD;

EID: 84975321465     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (20)

1. Berden FA, Kievit W, Baak LC, et al. Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era. Neth J Med. 2014;72:388-400.
2. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368:34-44.
3. Sulkowski MS, Jacobson IM, Nelson DR. Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med. 2014;370:1560-1.
4. Arends JE, van der Meer JT, Posthouwer D, et al. Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients. Neth J Med. 2015;73:324-30.
5. Willemse SB, Razavi-Shearer D, Zuure FR, et al. The estimated future disease burden of hepatitis C virus in the Netherlands with different treatment paradigms. Neth J Med. 2015;73:417-31.
6. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis. 2008;51:263-77.
7. Liu CH, Huang CF, Liu CJ, et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med. 2013;159:729-38.
8. Van Leusen R, Adang RP, de Vries RA, et al. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant. 2008;23:721-5.
9. Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat. 2007;14:697-703.
10. Singh N, Neidlinger N, Djamali A et al. The impact of hepatitis C virus donor and recipient status on long-term kidney transplant outcomes: University of Wisconsin experience. Clin Transplant. 2012;26:684-93.
11. Gilead D. Sofosbuvir for treatment of chronic hepatitic C infection. Antiviral drugs advisory committee briefing document.Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/antiviraldrugsadvisorycommittee/ucm371877.pdf. Epub 25 October 2013.
12. Singh T, Guirguis J, Anthony S, Rivas J, Hanouneh IA, Alkhouri N. Sofosbuvir based treatment is safe and effective in patients with chronic hepatitis C infection and end-stage renal disease: a case series. Liver int. 2016. Epub 2016/01/30.
13. Cornpropst MT, Denning JM, Clemons D, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977. J Hepatol. 2012;56:S433-S.
14. Gane EJ, Robson RA, Bonacini M, et al. Safety, Anti-Viral Efficacy and Pharmacokinetics (PK) of Sofosbuvir (SOF) in Patients with Severe Renal Impairment. Hepatology. 2014;60:667A-A.
15. Hundemer GL, Sise ME, Wisocky J, et al. Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infect Dis (Lond). 2015;47:924-9.
16. Nazario HE, Ndungu M, Modi AA. Sofosbuvir and Simeprevir in Hepatitis C genotype 1- patients with End-Stage Renal Disease on hemodialysis or GFR <30mL/min. Liver Int. 2015. Epub 2015/11/20.
17. Peck-Radosavljevic M, Boletis J, Besisik F, et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clin Gastroenterol Hepatol. 2011;9:242-8.
18. Kalyan Ram B, Frank C, Adam P, et al. Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease. J Hepatol. 2015;63:763-5.
19. Pockros PJ, Reddy KR, Mantry PS, et al. Safety of Ombitasvir/Paritaprevir/ Ritonavir plus Dasabuvir for treating HCV Gt1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-I study. J Hepatol. 2015;62:S257-S.
20. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537-45.